---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023478"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:18:41.433387+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VYNE Q1 net loss $8.6M; VYN202 psoriasis trial on clinical hold; repibresib vitiligo data due mid-2025

## Summary
- Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.
- R&D expenses $6.1M, up from $3.7M, driven by VYN202 and repibresib trials.
- Phase 1b psoriasis trial of VYN202 placed on clinical hold after testicular toxicity in dogs.
- Repibresib gel Phase 2b vitiligo top-line results expected mid-2025; fully enrolled.
- Revenue $0.2M from LEO Pharma royalty; cash runway into 2H 2026.

## SEC filing metadata
- accession: 0001628280-25-023478
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/0001628280-25-023478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/mnlo-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023478
- JSON: https://secwatch.observer/filing/0001628280-25-023478.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.